Dual Cardiorenal Coverage in Type 2 Diabetes: A Comprehensive Systematic Review and Meta-Analysis of GLP-1 Receptor Agonist and SGLT-2 Inhibitor Combination Therapy Versus Monotherapy Across Cardiovascular, Renal, and Metabolic Endpoints